Department of Biology, Center for Bionanotechnology and Environmental Research, Texas Southern University, Houston, TX, USA.
Expert Rev Vaccines. 2012 Jun;11(6):659-61. doi: 10.1586/erv.12.34.
Yersinia pestis (YP) is the Gram-negative etiological agent of plague against which no commercial vaccine exists to prophylactically prevent a potential outbreak due to natural or bio-warfare/terrorism-mediated causes. The US FDA only recently approved levofloxacin to combat this deadly pathogen. In the article under review, an attenuated, recombinant Salmonella typhimurium ΔphoPQ mutant strain producing YP antigens F1, LcrV and F1-V (fusion protein) from either low-copy pBR or high-copy pUC vectors (maintained by plasmid addiction rather than antibiotic selection pressure) were evaluated for their ability to induce a humoral immune response in both mice and rabbits. This study highlights the need for developing a well-tolerated YP vaccine that, through the oral route, can be readily administered and elicit both mucosal and systemic anti-plague humoral immunity.
鼠疫耶尔森菌（YP）是革兰氏阴性的病原体，可引起鼠疫，目前尚无针对该病原体的商业疫苗来预防因自然或生物战争/恐怖主义引起的潜在爆发。美国食品和药物管理局（FDA）最近才批准左氧氟沙星来对抗这种致命病原体。在审查的文章中，研究人员评估了一种减毒的重组鼠伤寒沙门氏菌ΔphoPQ 突变株，该突变株来自低拷贝数的 pBR 或高拷贝数的 pUC 载体（通过质粒依赖性而不是抗生素选择压力来维持），可产生 YP 抗原 F1、LcrV 和 F1-V（融合蛋白），以评估其在小鼠和兔子中诱导体液免疫应答的能力。这项研究强调了开发一种耐受性良好的 YP 疫苗的必要性，这种疫苗可通过口服途径给药，既可以引发黏膜免疫，也可以引发系统性抗鼠疫体液免疫。
